Message #25 From:
NewsBot Date: March 6, 2007 06:18:00 AM
ZYNX News Zynex Announces Increased Orders
LITTLETON, Colo.--(BUSINESS WIRE)--Zynex Medical Holdings, Inc. (OTCBB: ZYNX), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces an increase in its orders of 328% for February of 2007 compared to the same month last year and a 5% increase in orders compared to the month of January of this year.
“Our continued growth in orders is an important element in executing our strategic plan,” commented Thomas Sandgaard, CEO, “and we are excited that our products keep gaining market acceptance.”
Zynex received 621 orders in February 2007 versus 145 orders twelve months ago and 590 orders in January of 2007. Zynex has not yet finalized its results for the fourth quarter of 2006 and the 2006 fiscal year, including the impact of increased orders. Zynex will state these results in the Form 10-KSB for the 2006 fiscal year.
About Zynex Medical Holdings, Inc.
Zynex Medical Holdings, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, risks and delays associated with product development, risk of market acceptance of products, technology or product obsolescence, competitive risks, reliance on manufacturing partners, dependence on reimbursement from insurance companies, additional capital needs and other risks described in our Form 10-KSB for the year ended December 31, 2005.
